A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: Balancing efficacy with severity of dry mouth

BJU International

Volumn 97, Issue 3, 2006, Pages 520-527

  Corcos, Jaques ^a   Casey, Richard ^b   Patrick, Allan ^c   Andreou, Cal ^d   Miceli, Paula C ^e,f   Reiz, Joseph L ^e   Harsanyi, Zoltan ^e   Darke, Andrew C ^e  

^a MCGILL UNIVERSITY   (Canada)

^b Oakville Trafalgar Memorial Hospital   (Canada)

^c River Valley Health   (Canada)

^d SURREY MEMORIAL HOSPITAL   (Canada)

^e PURDUE PHARMA L P   (United States)

^f NONE   (Canada)

Author keywords

Bladder; Cholinergic antagonist; Drug delivery systems; Patient satisfaction; Pharmacology; Urinary incontinence

Indexed keywords

OXYBUTYNIN;

ADULT; AGED; ARTICLE; BLURRED VISION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRY THROAT; FEMALE; HALITOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SATISFACTION; SOMNOLENCE; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; URINE INCONTINENCE; URINE RETENTION; XEROSTOMIA;

ADULT; AGED; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MANDELIC ACIDS; MIDDLE AGED; PATIENT SATISFACTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URINARY INCONTINENCE; XEROSTOMIA;

EID: 33645003584     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.06031.x     Document Type: Article

References (28)

1. Abrams P Cardozo L Fall M et al. The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society Neurourol Urodyn 2002 21 167 78
2. Rovner ES Wein AJ Modern pharmotherapy of urge urinary incontinence in the USA: tolterodine and oxybutynin BJU Int 2000 86 Suppl. 2 44 54
3. de Groat WC A neurologic basis for the overactive bladder Urology 1997 50 Suppl. 6A 36 56
4. Yarker YE Goa KL Fitton A Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability Drugs Aging 1995 6 243 62
5. Agency for Health Care Policy and Research. Urinary Incontinence in Adults: Acute and Chronic Management: Clinical Practice Guideline #2 AHCPR Publication No. 96-0682. Rockville, MD US Department of Health and Human Services, Public Health Service Agency for Healthcare Policy and Research 1996
6. Sine K Oxybutynin chloride On Contin Pract 1984 11 31 3
7. Barkin J Corcos J Radomski SB et al. A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence Clin Ther 2004 26 1026 36
8. Anderson RU Mobley D Blank B Saltzstein D Susset J Brown JS Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence J Urol 1999 161 1809 12
9. Versi E Appell R Mobley D Patton W Saltzstein D Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group Obstet Gynecol 2000 95 718 21
10. Davila GW Daugherty CA Sanders SW for the Transdermal Oxybutynin Study Group. A short-term, multicenter, randomized, double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence J Urol 2001 166 140 5
11. Leslie ST Continus controlled release preparations Br J Clin Pract Symp Suppl 1980 10 5 8
12. max and dissolution rate Proceedings of American Association of Pharmaceutical Scientists Annual Meeting and Exposition 2001 October 21-5 Denver, Colorado
13. Reiz JL Darke AC Steady- state pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin Can J Clin Pharmacol 2003 10 131
14. Radomski SB Caley B Reiz JL Miceli PC Harsanyi Z Darke AC Pilot evaluation of a new formulation of once-daily controlled-release oxybutynin in the treatment of urinary incontinence Curr Med Res Opin 2004 20 249 53
15. Canadian Consensus Conference on Urinary Incontinence. Clinical Practice Guidelines for Adults Westmount, QC The Canadian Continence Foundation 2001 Available at:. Accessed September 2005
16. Health Canada. Dose Response Information to Support Drug RegistrationICH Topic E4 Health Products and Food BranchCatalogue no1142-2/67-4-1994E Ottawa Health Canada Publications 1994
17. Gleason DM Susset J White C Munoz DR Sand P Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group Urology 1999 54 420 3
18. Burgio KL Locher JL Goode PS et al. Behavioural vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial JAMA 1998 280 1995 2000
19. Gupta SK Sathyan G Lindemulder EA Ho PL Sheiner LB Aarons L Quantitative characterization of therapeutic index: application of mixed-effects modelling to evaluate oxybutynin dose-efficacy and dose-side effect relationships Clin Pharmacol Ther 1999 65 672 84
20. Bemelmans BL Kiemeney LA Debruyne FM Low-dose oxybutynin for the treatment of urge incontinence: good efficacy and few side effects Eur Urol 2000 37 709 13
21. Chancellor MB Sathyan G Gupta SK Spit study to compare different formulations of oxybutynin: a pharmacokinetic-pharmacodynamic study J Urol 1999 161 256a
22. Myers JL Well AD Research Design and Statistical Analysis New Jersey Lawrence Erlbaum Associates 1995
23. Diokno AC Appell RA Sand PK et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA Trial Mayo Clin Proc 2003 78 687 95
24. Tapp AJ Cardozo LD Versi E Cooper D The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double-blind placebo controlled study Br J Obstet Gynaecol 1990 97 521 6
25. Thuroff JW Bunke B Ebner A et al. Randomized, double-blind multicentre trial on treatment of frequency, urgency, and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo J Urol 1991 145 813 7
26. Hashimoto K Ohnishi N Esa A Sugiyama T Park Y Kurita T Clinical efficacy of oxybutynin on sensory urgency as compared with that on motor urgency Urol Int 1999 62 12 6
27. Abrams P Freeman R Anderstrom C Mattiasson A Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder Br J Urol 1998 81 801 10
28. Drutz HP Appell RA Gleason D Klimberg I Radomski S Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder Int Urogynaecol J Pelvic Floor Dysfunct 1999 10 283 9